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Regulation of interleukin.2 and interferon-y gene expression in renal
failure. Regulated expression of interleukin-2 (IL-2) and interferon-y
(IFN-y) genes, induced in cultured peripheral blood mononuclear cells
from patients with end-stage renal disease on hemodialysis (HD; N =
13) or peritoneal dialysis (PD; N = 13), was compared to that of 32
normal donors. Culture conditions were chosen that measure the
transient, phytohemagglutinin-induced expression of IL-2 and IFN-y
messenger RNA (mRNA), as well the intactness of post-transcriptional
and suppressor T cell-dependent mechanisms that control this expres-
sion. The latter was achieved by analyzing the superinduction of IL-2
and IFN-y mRNA occurring upon culture with cycloheximide or after
low-dose y-irradiation, respectively. HD subjects showed a complete
loss of inducibility of the IL-2 gene, concomitant with decreased
inducibility ofIFN-ymRNA. In PD subjects, by contrast, expression of
IL-2 mRNA was as vigorous as in normal donors, while IFN-y mRNA
was even more strongly inducible. This difference in gene inducibility is
caused by a lack of T cell function in HD subjects. The defect in IL-2
gene expression in HD subjects, occurring most likely at transcription,
may underly their impaired immune function.
Interleukin-2 (IL-2) is the essential growth factor for all types
of T cells [1], induced upon antigenic or mitogenic stimulation
[2] by helper T lymphocytes [3]. IL-2 is able to induce cytotoxic
T cell activity [4] and to activate natural killer cells [5]. The
strength of an immune response is determined to a large extent
by the amount of IL-2 elicited by a stimulus [6]. Interferon-y
(IFN-y) is also an essential immunoregulatory protein [71 with
antiviral activity [8] that activates macrophages [9] as well as
natural killer cells [10], and exhibits potent anti-tumor activity
in synergy with the tumor necrosis factors [11].
Expression of human IL-2 and IFN-y genes is induced by
mitogens or antigens. This process requires synthesis of new
RNA molecules and results in the appearance of a wave of
messenger RNA (mRNA) [12—151. The amplitude of the IL-2
and IFN-y mRNA waves can be superinduced extensively in
the presence of inhibitors of translation such as cycloheximide
(dx), yet the shape of each wave remains unchanged [13—16].
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A corresponding superinduction of IL-2 and IFN-y protein is
observed upon the removal of CHX [13, 15]. These findings
support the view that expression of IL-2 and IFN-y genes is
down-regulated strongly through a mechanism involving a labile
protein component. This mechanism acts after transcription of
the genes has occurred [14, 151.
A second mechanism regulating expression of IL-2 and
IFN-y genes involves suppressor cells. A transient activation of
T cells, able to suppress IL-2 and IFN-y gene expression,
occurs concomitant with the induction of expression of these
genes in human tonsil cell populations [17]. Expression of IL-2
[17] and IFN-y [15] mRNA and protein can be superinduced by
low doses of y-irradiation, a treatment thought to prevent the
activation of suppressor T cells. The effect of y-irradiation is
also exerted after transcription [15].
Humoral and cellular immune responses are impaired in
chronic renal failure [18]. Uremic patients are more susceptible
to bacterial infections [19] and malignancies [20], show delayed
cutaneous hypersensitivity to various antigens [21], a dimin-
ished response to immunization [22], lymphocytopenia [23] and
prolonged graft survival [24]. Defects in cellular immunity
include a reduction in number of circulating B and T lympho-
cytes [25], a reduced helper to suppressor T cell ratio [26], and
significantly impaired E-rosetting and blast transformation [21].
While hemodialysis (HD) does not restore these defects [18],
patients on peritoneal dialysis (PD) exhibit a better immune
response [18, 25, 27].
Thus far, it is unclear how the production of cytokines is
affected in uremic patients. While decreased T cell colony
formation [28], T cell function [29] and secretion of IL-2 [30, 31]
were observed in some studies, increased production of IL-2
[32] and IFN-y [33] were also reported. To obtain more precise
insight into the molecular basis underlying defective immune
cell function in end-stage renal disease, we have followed the
dynamics of IL-2 and IFN-y gene expression and its control.
We report here that expression of these genes differs strikingly
in HD and PD subjects. HD subjects exhibit a loss of inducibil-
ity of the IL-2 gene and decreased inducibility of the IFN-y
gene. In PD subjects, by contrast, the induction of IL-2 mRNA
is as vigorous as in normal donors, while IFN-y mRNA is even
more strongly inducible.
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Methods
Patients
Patients with end-stage renal disease. Thirteen ESRD pa-
tients who were on HD for 56.8 31.7 months (range, 11 to
120), aged 57 16.7 years (range, 22 to 78), had serum
creatinine on the day of study at 10.89 2.33 mg%, hematocrit,
27.83 0.88%, and blood urea nitrogen, 79.35 3.3 mg%.
Thirteen patients on PD [either intermittent peritoneal dialysis
(IPD, N = 9) or continuous ambulatory peritoneal dialysis
(CAPD, N = 4)] for 25.2 24.7 months (range, 7 to 95), aged 61
13.4 years (range, 28 to 76), had serum creatinine on the day
of study of 10.05 2.74 mg%, hematocrit, 20.97 2.67%, and
urea, 65.96 4.57 mg%. Blood was collected before dialysis.
Thirty-two normal donors, aged 33.2 2.2 years (range, 19 to
65) had serum creatinine of approximately 1 mg%. Male-to-
female ratio was about one in each group.
Studies
Cell culture and induction of gene expression. From 10 to 30
ml of peripheral blood per donor, mononuclear cells (PBMC)
were isolated by standard methods, washed and cultured at a
density of 0.5 to 4 x 106 cells/mi in 5 ml of culture medium
containing 2% fetal calf serum [34]. For each subject, 1-mi cell
cultures were incubated: (A) for 18 hours in the absence of
inducer; (B) for 18 hours with 0.4% (vol/voi) PHA-P (Difco,
Detroit, Michigan, USA); (C) for 22 hours with PHA; (D) for 22
hours with PHA, but with CHX (20 g/ml) from 18 to 22 hours;
(E) for 22 hours with PHA, but after y-irradiation of the cells
with a dose of 1,500 rad [34].
Quantitation of CD4, CD8 and total T cells. PBMC were
incubated with monoclonal mouse anti-human CD3, CD4, or
CD8 antibodies (Leul, Leu3a, and Leu2a, respectively, from
Becton and Dickinson) and FITC goat anti-mouse IgG (Coul-
ter). Total T cells, CD4, and CD8 cells were counted by
fluorescence microscopy.
Plasmids and hybridization probes. Human IL-2 DNA (p3-16
from T. Taniguchi) [35], IFN-y cDNA (pBR327 from R.
Devos and W. Fiers) [36], and a 1.1 Kb fragment of a-actin
cDNA [37] were placed under the phage T7 promoter in
pGEM-3 (Promega Biotec) to generate anti-sense RNA tran-
scripts labeled with [a-32P]ATP [38]. In total RNA isolated from
PBMC induced with phytohemagglutinin (PHA) [15], IL-2 and
IFN-y antisense RNA transcripts hybridize to RNA migrating
at 1,000 and 1,300 nt, respectively, as expected for mRNA,
comprising over 85% of the total hybridization signal; remaining
hybridization is to larger, precursor forms of IL-2 and IFN-y
mRNA. Sense RNA, generated from the SP6 promoter, gave no
detectable hybridization.
Quantitation of specific mRNA in cultured cells
The procedure is described elsewhere in detail [34]. Cells
from each culture were collected and lysed in 7.5 M guanidin-
ium-HC1 [39]. RNA was precipitated overnight in ethanol at
—20°C, dissolved into formaldehyde and incubated for 15
minutes at 60°C. Eight serial two-fold dilutions, made in 10 x
saline sodium citrate, were applied in duplicate to nitrocellulose
sheets, using a 96-well dot blot apparatus. After baking at 80°C
in a vacuum oven, sheets were hybridized separately with
32P-labeled RNA probes for IL-2 and IFN-y, respectively. Each
hybridization included a strip of nitrocellulose containing seri-
ally diluted RNA from a standard RNA preparation, purified
from human tonsil cells induced with PHA for 24 hours [12, 34].
A single standard RNA preparation was used for all donors in
this study. Exposed autoradiograms were scanned at 630 nm in
an ELISA reader. For each dilution series, hybridization inten-
sities were subjected to linear regression analysis. The slope is
proportional to the mRNA concentration for the gene being
probed. This value is expressed as standard units of mRNA/cell
[341.
Statistical analysis
All results are given as means SEM. Significance of the
difference of means was examined by the paired, two-tailed




To allow sensitive and quantitative measurement of specific
RNA expressed in microcultures of PBMC derived from 1 ml of
peripheral blood, we devised an adaptation [34] of a method for
detecting gene expression [39]. It is thus possible to analyze the
dynamics of IL-2 and IFN-y gene expression starting with as
little as 10 ml of peripheral blood. Hybridization intensity,
measured by determination of the slope of linear regression
analysis of serial dilutions of each RNA sample in dot blots, is
linear not only with amount of RNA but also with cell number
and can be detected over a 200-fold range [34]. Enhancement or
inhibition of RNA expression is reflected by corresponding
changes in levels of IL-2 and IFN-y protein produced (not
shown), showing that the RNA levels in dot blot hybridizations
reflect active gene expression in a manner that is representative
of mRNA. Specific mRNA content for a culture can be ex-
pressed in terms of standard units of mRNA per cell, allowing
direct comparison of results obtained with individual subjects
[34].
To facilitate analysis of regulated expression of IL-2 and
IFN-y genes in PBMC derived from subjects with renal failure,
we defined a set of conditions that measure not only the induced
expression of these genes, but also the intactness of mecha-
nisms that control their expression. Five different conditions of
induction were chosen (Methods), based on earlier studies of
the regulation IL-2 and IFN-y gene expression in mononuclear
cells from tonsils or peripheral blood [34]. A wave of IL-2 and
IFN-y mRNA is induced by exposure to PHA, reaching a
maximum for both genes in the 18 to 22 hour time range [13, 15].
The amplitude of the waves of mRNA can be superinduced in
the presence of inhibitors of translation, for example, CHX [13,
15]. Expression of IL-2 [17] and IFN-y genes [15] into mRNA
and active protein can also be superinduced by exposing cells,
before mitogenic stimulation, to low doses of y-irradiation that
prevent activation of suppressor T cells. These conditions of
induction are designed to determine if IL-2 and IFN-y genes are
inducible and if the two major post-transcriptional mechanisms
regulating their expression, involving a CHX-sensitive compo-
nent on one hand and suppressor T cells on the other, are
functioning normally.
Normal donors
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Normal donors
Expression of IL-2 and IFN-y genes in cells derived from 32
normal donors is shown in Figure 1. mRNA for both genes is
induced by PHA (compare A with B or C), expression increas-
ing between 18 and 22 hours (compare B with C), and responds
to superinduction by CHX (compare D with C). The IFN-y gene
is, however, significantly more sensitive to superinduction by
y-irradiation (compare E with C).
Subjects on dialysis
Induction of IL-2 and IFN-y genes in cells derived from 13
HD subjects is analyzed in Figure 2. Comparison of Figures 1
and 2 reveals a complete lack of inducibility of the IL-2 gene in
cells from HD individuals, even when CHX is present. The
IFN-y gene, by contrast, is inducible in HD subjects, although
to a lower extent than in normal donors, and is responsive to
superinduction by CHX and, more weakly, by y-irradiation.
Cells from HD subjects thus show a severe impairment in IL-2
gene expression and decreased activity of the IFN-y gene.
Figure 3 shows that in cells derived from 13 PD subjects, by
contrast, IL-2 and IFN-y genes remain inducible. mRNA for
both genes is superinducible by CHX and the IFN-y gene also
responds to y-irradiation. Comparison of Figures 1 and 3
reveals that on average, twofold lower levels of IFN-y mRNA
are expressed in PD subjects. IL-2 gene expression is reduced
even less.
Expression of the a-actin gene was followed concurrently in
these experiments as a control. Mitogenic stimulation of PBMC
leads to the induction of mRNA encoded by this gene. How-
ever, in contrast to the clear difference in IL-2 gene inducibility
observed between HD subjects and PD subjects or normal
donors, there was no significant difference between the three
groups in a-actin gene expression (not shown).
Comparison of HD, PD and normal subjects
Figure 4 depicts the indices of induction and superinduction
of IL-2 and IFN-y mRNA, respectively, in the population of
normal donors, HD subjects, and PD subjects. Index of induc-
tion is defined as the ratio of specific mRNA levels expressed
after culture in the presence of PHA for 18 hours (P) or 22 hours
(Q) and in its absence. Index of superinduction R is defined as
the ratio of specific mRNA levels induced after culture in the
presence of CHX for four hours and in its absence. Index of
superinduction S is defined as the ratio of specific mRNA levels
induced in cells after y-irradiation and induced directly. Induc-
tion or superinduction occurs only if the index exceeds I.
Comparison of IL-2 and IFN-y gene expression in Figure 4
shows that in all subjects, induction of IFN-y mRNA is twofold
greater (P and Q). Both genes are superinduced to a similar
extent in the presence of CHX (R). Though in normal donors
IFN- y mRNA is superinduced significantly upon y-irradiation
(S), that is not the case for IL-2 mRNA. The most pronounced
differences in expression of IL-2 and IFN-y genes, however,
concern HD and PD subjects.
As seen from Figure 4, indices of induction P and Qfor the
IL-2 gene do not exceed 1 in HD subjects, but are essentially
normal in PD subjects. In HD subjects, the IL-2 gene can be
superinduced by CHX, but not to a statistically significant
extent (R). In PD subjects, on the other hand, the index of
Fig. 1. Regulated expression of IL-2 and IFN-y genes in 32 normal
donors. lL-2 and IFN-y mRNA were quantitated, in standard units/cell, in
PBMC from each donor, cultured in 5 different conditions: (A) uninduced;
(B) induced with PHA for 18 hours; (C) induced with PHA for 22 hours;
(D) induced with PHA for 22 hours, but with CHX present between 18 and
22 hours; and (E) y-irradiated before induction with PHA for 22 hours.
superinduction of IL-2 mRNA by CHX is at least equal to that
seen in normal donors.
A clear difference between HD and PD subjects is revealed
also by analysis of the inducibility of the IFN-y gene (Fig. 4).
While IFN-y mRNA is inducible in all conditions studied,
indices of induction P and Q are distinctly lower than normal in
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Fig. 2. Regulated expression of IL-2 and IFN-y genes in 13 subjects
with end-stage renal disease on hemodialysis. IL-2 and IFN-y mRNA
was quantitated, in standard units/cell, in PBMC from each donor,
cultured in 5 different conditions (A-E; Fig. I legend),
IFN-y mRNA is superinduced by CHX to a normal extent in
HD subjects, yet more vigorously in PD subjects (R). In all
three groups, the IFN-y gene responds similarly to y-irradia-
tion, but superinduction is significant only for normal donors.
One-way analysis of variance for all five conditions of induc-
tion and superinduction, shown in Figures 1 to 3, yielded
significant responses for normal donors (P < 0.00001 for the
IL-2 gene and P = 0,0001 for the IFN-y gene) and PD subjects
Fig. 3. Regulated expression of IL-2 and IFN-y genes in 13 subjects
with end-stage renal disease on peritoneal dialysis. IL-2 and IFN-y
mRNA was quantitated, in standard units/cell, in PBMC from each
donor, cultured in 5 different conditions (A-E; Fig. I legend).
(P = 0.06 for IL-2 and P 0.02 for IFN-y), while for the HD
group these were not significant (P = 0.79 for IL-2 and P = 0.39
for IFN-y).
Role of T cells in induced gene expression
CD4/CD8 ratios [34] for the HD and PD patient populations
were indistinguishable (1.20 0.08 and 1.22 0.07, respective-
ly), yet below the value of 1.4 0.12 obtained for the normal
Induction ratio
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106/ml vs. PD: 1.86 0.29 x 106/ml, P = 0.05), raising the
possibility that this difference could explain the discrepancy in
inducibility observed between Figures 2 and 3.
To examine this point, levels of induction were analyzed for
each donor as standard units of mRNA per T cell. As seen in
Table 1, when expressed per T cell, induction of IL-2 and IFN-y
genes was still insignificant in HD subjects (P > 0.05), yet
significant in PD subjects. Hence, the lack of inducibility
observed for HD subjects is caused by defective function of
their T cells, rather than by a lack of T cells.
Discussion
Fig. 4. Index of induction and superinduction of IL-2 and IFN-y
mRNA in PBMC from normal donors (CTRL), HD and PD subjects.
Ratios of specific RNA values expressed in PBMC were calculated for
each individual donor of the groups shown in Figures 1 to 3 and then
averaged: 18 hours induced/uninduced (P); 22 hours induced/uninduced
(Q); 22 hours induced, with CHX added at 18 hr/22 hr induced (R); 22
hours induced after y-irradiationl22-hours induced (S). (*) P < 0.05 in
the paired, two-tailed f-test.
donors analyzed. On the other hand, when activity of PBMC
was examined by measuring incorporation of 3H-labeled thymi-
dine induced over 24 hours by PHA, a stimulation index of 28.5
7.6 was obtained for HD subjects, significantly lower (P <
0.05) than that for PD subjects (51.6 8) and normal donors
(51.4 4.3). The total number of CD3 T cells/mi also differed
for the two groups of dialysis subjects (HD: 1.16 0.19 x
Using a sensitive and quantitative assay for specific mRNA,
capable of measuring mRNA levels expressed in cells from as
little as I ml of peripheral blood [34], we have analyzed the
regulated expression of IL-2 and IFN-y mRNA in PBMC from
subjects with end-stage renal disease, on either HD or PD, and
compared it to that of normal donors. HD subjects exhibit a
striking loss of inducibility of the IL-2 gene, concomitant with
decreased inducibility of IFN-y mRNA. In PD subjects, by
contrast, expression of IL-2 mRNA is as vigorous as in normal
donors, while IFN-y mRNA is even more strongly inducible.
These anomalies in gene expression appear to be specific, as
they are not reflected in the expression of a reference gene, that
for a-actin, and thus may underly impaired immune function in
subjects with chronic renal failure on HD, as opposed to a far
more normal response in those on PD.
Patients on PD (or CAPD) show better immune responsive-
ness than those on HD [27]. Lectin-induced blast transforma-
tion of lymphocytes is equal in CAPD patients and normal
donors, but lower in HD subjects [41]. IFN-y production and T
cell function improve progressively with CAPD treatment [25].
The biological responses measured in these [25, 27, 411 and
other studies [28—33] are, however, the cumulative result of a
sequence of events. Determination of mRNA, on the other
hand, gives dynamic information about gene function and is
more direct and specific. Here, we have quantitated mRNA
levels for IL-2 and IFN-y, two key immunoregulatory proteins,
in cells subjected to a plurality of culture conditions, allowing
assessment not only of inducibility of the genes but also of
appropriate control of their expression by post-transcriptional
and suppressor T cell-dependent mechanisms. Since IL-2 and
IFN-y mRNA are expressed transiently, aberrations in gene
expression are most readily detected early in the induction
process. By comparing the performance of IL-2 and IFN-y
genes, as we have done, aberrant expression of either is
detected with greater sensitivity.
Expression of both genes is down-regulated by a mechanism
involving a labile protein whose neutralization, in the presence
of CHX, leads, in both normal donors and PD subjects, to
extensive superinduction of mRNA levels expressed upon
mitogenic stimulation (Figs. 1 and 3). In HD subjects, the IFN-y
gene also responds with a significant superinduction, but IL-2
gene expression is not restored to normal values when CHX is
present (compare Figs. 1 and 2). It is unlikely that the CHX-
sensitive mechanism has become CHX-resistant in HD sub-
jects. Excessive repression of the IL-2 gene by the CHX-
sensitive mechanism thus cannot explain the lack of expression.
The transient induction of IL-2 and IFN-y gene expression
was assessed at 18 and 22 hours, times determined as optimal
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for non-uremic subjects in earlier studies [12, 13, 15, 34]. In the
present experiments, transient expression patterns for IL-2 and
IFN-y genes (Figs. I to 3) show great similarity for normal and
PD subjects. This similarity does not support the interpretation
that the distinct pattern displayed by HD subjects is based on
markedly different kinetics of IL-2 gene expression, although
this explanation remains possible. A kinetic basis for the
observed difference is also not supported by the fact that HD
subjects show a distinct lack of response to CHX, since in cells
from normal donors, expression of the IL-2 gene can be
superinduced by CHX, whether it is added before, during or
after the wave of mRNA expression [13, 14].
Expression of IL-2 and IFN-y genes is also controlled by the
action of suppressor T cells [17]. Although a decrease in the
CD4 (helper) over CD8 (cytotoxic/suppressor) cell subset ratio,
reported in chronic renal failure [26], is confirmed in this study,
HD and PD subjects exhibited no difference in CD4ICD8 ratio.
In PBMC from normal donors, expression of IFN-y mRNA, but
not that of IL-2 mRNA, is superinduced by exposure of cells to
y-irradiation prior to induction (Figs. I and 4). Apparently, the
IFN-y gene is far more sensitive than the IL-2 gene to down-
regulation by suppressor T cells. Hence, if enhanced suppres-
sor T cell activity were to occur in HD, a selective inhibition of
IFN-y gene expression would have been expected. This is not
the case. Instead, expression of the IL-2 gene is selectively
impaired and cannot be restored, even in part, by y-irradiation
(Figs. 2 and 4). Thus, the failure of IL-2 gene expression in HD
is not readily explained by enhanced y-irradiation-sensitive
suppressor T cell activity. Since y-irradiation is thought to
inhibit the activation of suppressor cells but not to affect active
ones, the results leave open the possibility that PBMC from HO
subjects contain greater numbers of suppressor cells that were
preactivated in the donor, even though selective inhibition of
the IFN-y gene, rather than the IL-2 gene, would then have
been expected.
In PBMC from normal donors, induction of IFN-y mRNA is
about twofold greater than that of IL-2 mRNA (Fig. 4). Induc-
tion of these mRNA species requires de novo transcription [13,
15] which is apparently more vigorous for the IFN-y gene.
Induction of IFN-y mRNA is greatly enhanced in PD subjects,
when compared to normal donors (Fig. 4). In HD subjects, on
the other hand, induction of the IFN-y gene is lower than in
normal donors. The complete lack of inducibility of the IL-2
gene in HD subjects is indicative of reduced transcriptional
activity. Although quantitation of transcription rates would
require 50 times more PBMC than were used here [15], our
findings indicate that the impairment in IL-2 gene expression in
HD subjects is not caused by excessive down-regulation by
suppressor T cells, nor by the CHX-sensitive, post-transcrip-
tional mechanism, but most likely occurs at transcription.
In spite of general anemia associated with chronic disease,
the hematocrit in the group of HO subjects was actually 33%
higher (P = 0.09), showing that there is no correlation between
baseline hematocrit and decreased inducibility of IL-2 or IFN-y
genes. The mean age and age range of the groups of HD and PD
subjects studied here were closely similar, eliminating age as
explanation for the different gene expression patterns obtained
with these two groups. CD4/CD8 ratios also did not differ
between HD and PD groups, but HD subjects had a significantly
lower number of total T cells per ml of blood. Yet, as shown in
Table I. Significance of induction of IL-2 and IFN-y genes pe
in HD and PD subjects
r T cell




P value of (C, A): significance of induction was determined by
two-tailed, paired t-test analysis for values of A and C (legend to Fig. I
for conditions of induction), expressed for each individual donor as
standard units of mRNA per T cell.
Table I, correction for the difference in total T cell number does
not eliminate the lack of gene inducibility exhibited by PBMC
from HD subjects. Thus, lack of inducibility is caused by a lack
of T cell function. Indeed, PBMC from HD subjects incorpo-
rated less thymidine. These results, the IL-2 and IFN-y gene
expression patterns of Figures 1 to 4 and those for a-actin, all
support the concept that in HD, T cells are defective in induced
expression of the IL-2 gene and, to a lesser extent, the IFN-y
gene.
It is not clear how uremia leads to impaired T cell function.
HD sera contained 10% more plasma creatinine (P = 0.02) and
20% more blood urea nitrogen (P = 0.018). Uremic serum is
thought to have a predominant role [42], through toxicity of
accumulated substances [27, 43]. These sera, or their dialysate
[44], contain an activity that inhibits lectin-induced blast trans-
formation [43] and the graft-versus-host reaction [45]. CAPD is
more effective than HO in clearing this activity [46]. As seen
here, the IL-2 gene is more sensitive than the IFN-y gene to the
negative effects of uremia in HO subjects, although expression
of both is reduced severely.
Acknowledgments
Supported in part by grants from the Israel Academy of Sciences and
Humanities and the Wolfson Fund of The Hebrew University.
Reprint requests to Dr. Raymond Kaempfer, Department of Molec-
ular Virology, The Hebrew University-Hadassah Medical School, P. 0.
Box 1172, 91010 Jerusalem, Israel.
References
1. TEES R, SCHREIER MH: Selective reconstitution of nude mice with
long-term cultured and cloned specific helper T cells. Nature
283:780—781, 1980
2. GILLI5 S. FERM MM, Ou W, SMITH KA: T cell growth factor:
Parameters of production and a quantitative microassay for activ-
ity. J Immunol 120:2027—2032, 1978
3. SOLBACH W, BARTH 5, ROLLINGHOFF M, WAGNER H: Interactions
of human T cell subsets during the induction of cytotoxic T
lymphocytes: The role of interleukins. C/in Exp Immunol 49:167—
175, 1982
4. WAGNER H, HARDT C, HEEG K, ROLUNGHOFF M, PFIZENMAIER
K: T-cell derived helper factor allows in vivo induction of cytotoxic
T cells in nu/nu mice. Nature 284:278—280, 1980
5. HENNEY CS, KURIBAYASHI K, KERN DE, GILLI5 5: Interleukin-2
augments natural killer cell activity. Nature 29 1:335—338, 1981
6. ANDERSSON J, GR0vNIK KO, LAR550N EL, C0uTINH0 A: Studies
on T lymphocytes activation. I. Requirements for the mitogen-
dependent production of T cell growth factors. Eur J Immunol
9:581—587, 1979
7. PERUSSIA B, MANGONI L, ENGERS HD, TRINCHIERI G: Interferon
production by human and murine lymphocytes in response to
alloantigens. J Immunol 125:1589—1595, 1980
272 Gerez et a!: Regulation of IL-2 and IFN-y genes in CRF
8. RUBIN BY, GUPTA SL: Differential efficacies of human type I and
type II interferons as antiviral and antiproliferative agents. Proc
Natl Acad Sci USA 77:5928—5932, 1980
9. SVEDERSKY LP, BENTON CV, BERGER WH, RINDERKNECI-IT E,
HARKINS RH, PALLADINO MA: Biological and antigenic similarities
of murine interferon-gamma and macrophage-activating factor. J
Exp Med 159:812—827, 1984
10. CLAEYS H, VAN DAMME J, DE LEY M, VERMYLEN C, BILLIAU A:
Activation of natural cytotoxicity of human periferal blood mono-
nuclear cells by interferon: A kinetic study and comparison of
different interferon types. Brit J Haematol 50:85—94, 1982
II. BROUCKAERT PGG, LEROUX-ROELS GG, GUISEZ Y, TAVERNIERJ,
FIERS W: In vivo anti-tumour activity of recombinant human and
murine TNF, alone and in combination with murine IFN-y, on a
syngeneic murine melanoma. mt j Cancer 38:763—769, 1986
12. EFRAT S, PILO S, KAEMPFER R: Kinetics of induction and molec-
ular size of mRNAs encoding human interleukin-2 and gamma-
interferon. Nature 297:236—239, 1982
13. EFRAT 5, KAEMPFER R: Control of biologically active interleukin-2
messenger RNA formation in induced human lymphocytes. Proc
NatlAcadSci USA 81:2601—2605, 1984
14. KAEMPFER R, EFRAT S, MARSH S: Regulation of human interleu-
kin-2 gene expression, in Molecular Cloning and Analysis of
Lymphokines, edited by DR WEBB, D GOEDDEL, Orlando, Aca-
demic Press, 1987, pp. 59—72
15. LEBENDIKER MA, TAL C, SAYAR D, PIL0 S. BANAl Y, EILON A,
KAEMPFER R: Superinduction of the human gene encoding immune
interferon. EMBO J 6:585—589, 1987
16. EFRAT S, ZELIG S, YAGEN B, KAEMPFER R: Superinduction of
human interleukin-2 messenger RNA by inhibitors of translation.
Biochem Biophys Res Commun 123:842—848, 1984
17. KETZINEL M, EFRAT S, SAYAR D, GEREZ L, TAL C, DEUTSCH E,
ARAD G, KAEMPFER R: Regulation of human interleukin-2 and
interferon-gamma gene expression by suppressor T lymphocytes.
ScandJ immunol 33:593—605, 1991
18. SCI-1OLLMEYER P, BOZKURT F: The immune status of the uremic
patient: Hemodialysis vs CAPD. Cliii Nephrol 30 (Suppl l):37—40,
1988
19. KLEINKNECHT D, JUNGERS P, CHANARD J, BARBANEL C,
GANEVAL D: Uremic and non-uremic complications in acute renal
failure. Evaluation of early and frequent dialysis on prognosis.
Kidney mt 1:190—196, 1972
20. JACOBS C, BRUNNER FP, BRYNGER H, CHANTLER C, DONCKER-
WOLCKE RA, HATHWAY RA, KRAMER P, SELWOOD NH, WING
AJ: Malignant diseases in patients treated by dialysis and trans-
plantation in Europe. Transpi Proc 13:729—732, 1981
21. GOLDBLUM SE, REED WP: Immunological alterations in chronic
renal failure. Ann Intern Med 93:597—613, 1980
22. KOHLER H, ARNOLD W, RENSCHIN G, DORMEYER HH, MEYER
ZUM BUSCHENFELDE KH: Active hepatitis B vaccination of dialy-
sis patients and medical staff. Kidney ut 25:124—128, 1984
23. HoY WE, CESTERO RV, FREEMAN RB: Deficiency of T and B
lymphocytes in uremic subjects and partial improvement with
maintenance hemodialysis. Nephron 20:182—188, 1978
24. DAMMIN GJ, COUCH NP, URRAY JE: Prolonged survival of skin
homografts in uremic patients. Ann NYAcad Sci 64:967—976, 1957
25. L-IN CY, HUANG TP: Serial cell-mediated immunological changes
in terminal uremic patients on continous ambulatory peritoneal
dialysis therapy. Am J Nephrol 8:355—362, 1988
26. RASKA K, RASKOVA J, SHEA SM, FRANKEL RM, WOOD RH,
LIFTER J, GHOBRIAL 1, EISENGER RP, HOMER L: T cell subsets and
cellular immunity in end stage renal disease. Am J Med 75:734—740,
1983
27. GIACCHINO F, QUARELLO F, PELLEREY M, PiccoLl G: Continuous
ambulatory peritoneal dialysis improved immunodeficiency in ure-
mic patients. Nephron 35:209—210, 1983
28. WAKABAYASHI Y, SUGIMOTO M, ISHIYAMA T, H0RIE S, ABE S,
HIROSE S. OKUDA T: Studies on T-cell colony formation in chronic
renal failure (CRF) patients. Clin Nephrol 32:270—275, 1989
29. KUI&Z P, KOHLER H, MEUER S, HUTTEROTH T, MEYER ZLJM
BUSCHENFELDE KH: Impaired cellular immune responses in
chronic renal failure: Evidence for a I cell defect. Kidney mt
29:1209—1214, 1986
30. RASKOVA J, GHOBRIAL 1, SHEA SM, EBERT EC, EISINGER RP,
RASKA K: T cells in patients undergoing chronic hemodialysis:
Mitogenic response, suppressor activity, and interleukin-2 produc-
tion and receptor generation. Diagn Immuno! 4:209—216, 1986
31. BEAURAIN G, NARET C, MARCON L, GRATEAU 0, DRUEKE I,
URENA P, NELSON DL, BACH JF, CHATENOUD L: In vivo T cell
preactivation in chronic uremic hemodialyzed and non-hemodia-
lyzed patients. Kidney mt 36:636-644, 1989
32. KIMMEL PL, PHILLIPS TM, PHILLIPS E, BOSCH JP: Effect of renal
replacement therapy on cellular cytokine production in patients
with renal disease. Kidney mt 38:129—135, 1990
33. YOUSEFI S, VAzIRI ND, CARANDANG G, CESARIO T: Evaluation of
the in vitro production of interferon gamma and other lymphokines
in uremic patients. Proc Soc Exp Biol Med 184:179—185, 1987
34. GEREZ L, MADAR L, ARAD 0, SHARAV T, RESHEF A, KETZINEL
M, SAYAR D, SILBERBERG C, KAEMPFER R: Aberrant regulation of
interleukin-2 but not of interferon-y gene expression in Down
syndrome (trisomy 21). Clin Immunol Immunopathol 58:251—266,
1991
35. TANIGUCHI I, MATSUI H, FUJITA I, TAKAOKA C, KASHIMA R,
Y0sHIM0T0 N, HAMURO J: Structure and expression of a cloned
cDNA for human interleukin-2. Nature 302:305—310, 1983
36. DEVOS R, CHEROUTRE H, TAYA Y, DEGRAVE W, VAN HEUVER-
swyN H, FIERS W: Molecular cloning of human immune interferon
eDNA and its expression in eukaryotic cells. Nuci Acids Res
10:2487—2501, 1982
37. MINTY AJ, CARAVATTI M, ROBERT B, COHEN A, DAUBAS P,
WEYDERT A, Gos F, BUCKINGHAM MA: Mouse actin messenger
RNAs. J Biol Chem 256:1008—1014, 1981
38. MELTON DA, KRIEG PA, REBAGLIATI MR. MANIATIS I, ZINN K,
GREEN MR: Efficient in vitro synthesis of biologically active RNA
hybridization probes from plasmids containing bacteriophage SP6
promoter. NucI Acid Res 12:7035—7056, 1984
39. CI-IELEY 5, ANDERSON R: A reproducible microanalytical method
for the detection of specific RNA sequences by dot-blot hybridiza-
tion.AnalBiochem 137:15—19, 1984
40. ZAR JH: Biostatistical Analysis (2nd ed). Englewood Cliffs, Pren-
tice-Hall, Inc., 1984, pp. 150—153
41. LANGHOFF E, LADEFOGED J: Improved lymphocyte transforma-
tion in vitro of patients on continuous ambulatory peritoneal
dialysis. Proc EDTA 20:230—235, 1983
42, MUSATTI CC, SOARES VA, SANTOS LM, DE LIMA JJ, MENDES NF:
Immunosuppressive effect of soluble E-receptors in uremic serum.
Clin Immunol Immunopathol 24:403—410, 1979
43. TOURAINE JL, TOURAINE F, REVILLARD JP, BROCHIER J, TRAEGER
J: I lymphocytes and serum inhibitors of cell mediated immunity in
renal insufficiency. Nephron 14:195—208, 1975
44. NAVARRO J, GROSSETETE MC, DEFRASNE A, TOURAINEJL, TRAE-
GER J: Isolation of an immunosuppressive fraction in ultrafiltrate
from uremic sera. Nephron 40:396—400, 1985
45. NAVARRO J, TOURAINE JL, CORRE C, TRAEGER J: Prolongation of
skin allograft survival and inhibition of graft versus host in rodents
treated with middle molecular weight molecules. Cell Immunol
3 1:349-354, 1977
46. PopovIcH RP, MONCRIEF JW, NOLPH KD, GHODS AJ, TWARD-
OWSKI ZJ, PYLE WK: Continuous ambulatory peritoneal dialysis.
Ann Intern Med 88:449—456, 1978
